BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
53.30
-0.51 (-0.94%)
At close: Apr 28, 2026, 4:00 PM EDT
53.34
+0.04 (0.08%)
After-hours: Apr 28, 2026, 6:45 PM EDT
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for BioMarin Pharmaceutical stock have an average target of 88.22, with a low estimate of 55 and a high estimate of 119. The average target predicts an increase of 65.52% from the current stock price of 53.30.
Analyst Consensus: Buy
* Price targets were last updated on Mar 11, 2026.
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 6 | 6 | 6 |
| Buy | 9 | 8 | 8 | 7 | 8 | 8 |
| Hold | 5 | 6 | 6 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 21 | 17 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $97 → $85 | Strong Buy | Maintains | $97 → $85 | +59.47% | Mar 11, 2026 |
| Barclays | Barclays | Buy Maintains $80 → $105 | Buy | Maintains | $80 → $105 | +97.00% | Mar 4, 2026 |
| Freedom Broker | Freedom Broker | Strong Buy Maintains $100 → $105 | Strong Buy | Maintains | $100 → $105 | +97.00% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $55 | Hold | Reiterates | $55 | +3.19% | Mar 2, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $98 → $104 | Strong Buy | Maintains | $98 → $104 | +95.12% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
3.71B
from 3.22B
Increased by 15.02%
Revenue Next Year
4.16B
from 3.71B
Increased by 12.23%
EPS This Year
4.37
from 1.80
Increased by 142.29%
EPS Next Year
5.77
from 4.37
Increased by 31.95%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.2B | 4.8B | ||||||
| Avg | 3.7B | 4.2B | ||||||
| Low | 3.3B | 3.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 29.5% | 30.8% | ||||||
| Avg | 15.0% | 12.2% | ||||||
| Low | 1.2% | -11.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 6.34 | 9.18 | ||||||
| Avg | 4.37 | 5.77 | ||||||
| Low | 2.97 | 3.48 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 251.4% | 109.9% | ||||||
| Avg | 142.3% | 31.9% | ||||||
| Low | 64.5% | -20.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.